Pharmacy claims and clinical data from a 12-month period were used to evaluate medication persistence and health outcomes among these members, all of whom had recently begun GLP-1 therapy for weight loss at program start
Management: Only use under neurologist supervision Start with very low dose Monitor seizure frequency carefully Keep detailed seizure log Diabetes Medications Medications affected: Insulin Metformin Sulfonylureas (glyburide, glipizide) GLP-1 agonists (semaglutide, liraglutide) Interaction: Melatonin may affect glucose regulation, insulin sensitivity, and insulin secretion
Eli Lilly and Novo Nordisk dominate the GLP-1 market, and most payers secure access through competitive rebate contracts, offering discounts of 35%-50%
Refer to the dosing chart attached
It undergoes significant first-pass metabolism in the liver and intestines, where the enzyme arginase breaks it down, reducing bioavailability